Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Cipla

    Tag: Cipla

    You Searched For "Cipla"
    Cipla gets USFDA final approval for generic version of Proventil HFA Inhalation Aerosol

    Cipla gets USFDA final approval for generic version of Proventil HFA Inhalation Aerosol

    Medical Dialogues Bureau10 April 2020 10:00 AM IST
    Mumbai: Cipla Limited has announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate...
    Cipla completes Phase-3 clinical study for generic version of GSK Advair Diskus

    Cipla completes Phase-3 clinical study for generic version of GSK Advair Diskus

    Medical Dialogues Bureau5 April 2020 2:41 PM IST
    Mumbai: Cipla Limited has announced the successful completion of the Phase-3 clinical end-point study for fluticasone propionate and salmeterol...
    NPPA directs 3 pharma cos to maintain stock of atleast 2.2 crore tablets of FDC Lopinavir and Ritoavir

    NPPA directs 3 pharma cos to maintain stock of atleast 2.2 crore tablets of FDC Lopinavir and Ritoavir

    Medical Dialogues Bureau29 March 2020 1:19 PM IST
    New Delhi: The National Pharmaceuticals Pricing Authority (NPPA), Department of Pharmaceuticals directed 3 major manufacturers of the HIV Combo...
    Cipla gets USFDA final nod for Esomeprazole ANDA for Oral Suspension

    Cipla gets USFDA final nod for Esomeprazole ANDA for Oral Suspension

    Medical Dialogues Bureau27 March 2020 12:51 PM IST
    Cipla's Esomeprazole for Oral Suspension 10mg, 20mg and 40mg is an AB-rated generic therapeutic equivalent version of AstraZeneca Pharmaceutical's ...
    Cipla joins hands with CSIR-IICT to develop coronavirus drug

    Cipla joins hands with CSIR-IICT to develop coronavirus drug

    Medical Dialogues Bureau19 March 2020 12:10 PM IST
    Hyderabad: Hyderabad-based CSIR-Indian Institute of Chemical Technology (IICT) has tied up with pharmaceutical giant Cipla to work on the...
    Dr VG Somani DCGI releases IPA guidelines on Market Complaints.

    Dr VG Somani DCGI releases IPA guidelines on Market Complaints.

    Medical Dialogues Bureau2 March 2020 10:30 AM IST
    The guidelines were released at the recently concluded India Pharmaceutical Forum
    USFDA inspection at Cipla manufacturing facility in Goa, warning letter issued

    USFDA inspection at Cipla manufacturing facility in Goa, warning letter issued

    Medical Dialogues Bureau27 Feb 2020 1:56 PM IST
    New Delhi: Drug firm Cipla recently announced that it has received a warning letter from USFDA for its goa Manufacturing Facility.Pursuant to...
    Cipla arm inks pact for anti-psychotic drug Quetiapine

    Cipla arm inks pact for anti-psychotic drug Quetiapine

    Farhat Nasim11 Feb 2020 12:15 PM IST
    New Delhi: Cipla Medpro South Africa (Pty) Ltd, a wholly-owned subsidiary of Cipla Ltd, India, has recently concluded an exclusive agreement securing...
    Cipla acquires 4 key brands from Wanbury for up to Rs 89 crore

    Cipla acquires 4 key brands from Wanbury for up to Rs 89 crore

    Medical Dialogues Bureau10 Feb 2020 8:00 PM IST
    New Delhi: Drug firm Cipla on Saturday said it has acquiredfourbrandsfrom Wanbury Ltdto strengthen its presence in the women's health segment. ...
    Cipla acquires 4 nutrition products from Wanbury for Rs 89 crore

    Cipla acquires 4 nutrition products from Wanbury for Rs 89 crore

    Farhat Nasim10 Feb 2020 11:58 AM IST
    New Delhi: Homegrown pharma firm Cipla on Saturday announced the acquisition of nutrition products portfolio from Wanbury Ltd. The company has...
    Cipla Q3 revenue up by 13pc at Rs 4371 crore

    Cipla Q3 revenue up by 13pc at Rs 4371 crore

    Medical Dialogues Bureau6 Feb 2020 12:30 PM IST
    "We have had yet another good quarter: India business continued its momentum with strong double-digit growth in the prescription business; growth...
    Emcure plea to direct NPPA to review HIV drugs price junked by DoP

    Emcure plea to direct NPPA to review HIV drugs price junked by DoP

    Farhat Nasim3 Feb 2020 1:41 PM IST
    New Delhi: In a setback to drugmaker Emcure Pharmaceuticals, the Department of Pharmaceuticals (DoP) has rejected the company's petition seeking to...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok